Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 15:12:656362.
doi: 10.3389/fimmu.2021.656362. eCollection 2021.

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

Francesca Ferretti  1 , Rosanna Cannatelli  1 , Maurizio Benucci  2 , Stefania Carmagnola  1 , Emilio Clementi  3   4 , Piergiorgio Danelli  5 , Dario Dilillo  6 , Paolo Fiorina  7   8   9 , Massimo Galli  10 , Maurizio Gallieni  11   12 , Giovanni Genovese  13   14 , Valeria Giorgi  15 , Alessandro Invernizzi  16   17 , Giovanni Maconi  1 , Jeanette A Maier  11 , Angelo V Marzano  13   14 , Paola S Morpurgo  7 , Manuela Nebuloni  18 , Dejan Radovanovic  19 , Agostino Riva  11 , Giuliano Rizzardini  20   21 , Gianmarco Sabiu  11   12 , Pierachille Santus  11   19 , Giovanni Staurenghi  16 , Gianvincenzo Zuccotti  6 , Pier Carlo Sarzi-Puttini  15 , Sandro Ardizzone  1
Affiliations

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

Francesca Ferretti et al. Front Immunol. .

Abstract

Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.e. ChAdOx1 nCoV-19 (AstraZeneca), have recently been approved in Europe. Clinical trials on these vaccines have been published on the general population showing a high efficacy with minor adverse events. However, specific data about the efficacy and safety of these vaccines in patients with immune-mediated inflammatory diseases (IMIDs) are still lacking. Moreover, the limited availability of these vaccines requires prioritizing some vulnerable categories of patients compared to others. In this position paper, we propose the point of view about the management of COVID-19 vaccination from Italian experts on IMIDs and the identification of high-risk groups according to the different diseases and their chronic therapy.

Keywords: COVID-19; IMIDs; Sars-CoV-2; chronic disease; prevention; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Prioritization proposal according to patients’ individual-, occupational- and IMIDs-related risk factors. *According to ECDC (European Centre for Disease Prevention and Control) Technical Report (https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-and-prioritisation-strategies.pdf). **to evaluate; not included in the mathematical models.
See this image and copyright information in PMC

References

    1. Fda . Pfizer-BioNTech COVID-19 VaccineEmergency Use Authorization Review Memorandum. (2020). Available at: https://www.fda.gov/media/144416/download.
    1. Fda . Moderna COVID-19 VaccineEmergency Use Authorization Review Memorandum. (2020). Available at: https://fda.report/media/144673/Moderna+COVID-19+Vaccine+review+memo.pdf.
    1. EMA . https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-astra....
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med (2020) 383(27):2603–15. 10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med (2020) 384(5):403–16. 10.1056/NEJMoa2035389 - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources